Pfizer Inc. vs Samsung Electronics Co., Ltd.: Strategic Comparison

This in-depth comparison examines Pfizer Inc. and Samsung Electronics Co., Ltd. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Pfizer Inc. on its own, evaluating Samsung Electronics Co., Ltd., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Pfizer Inc. and Samsung Electronics Co., Ltd. is widest.

On the headline numbers, Pfizer Inc. reports annual revenue of $62.6B against $233.3B for Samsung Electronics Co., Ltd., while their respective market capitalizations stand at $148.0B and $1.20T. Pfizer Inc. is headquartered in United States and Samsung Electronics Co., Ltd. operates from South Korea, and those different home markets shape how each company competes.

Pfizer Inc.: Pfizer has repeatedly reinvented itself around new therapeutic waves, from industrial fermentation and penicillin to Lipitor, vaccines, COVID products, and now oncology. The 2025 profile is not a pandemic windfall story; it is a large pharmaceutical company trying to rebuild a durable growth base.

Samsung Electronics Co., Ltd.: Samsung is unusually broad for a technology company. It is a national industrial champion, a memory supplier, a smartphone competitor, a display maker, an appliance company, and an automotive electronics owner through Harman. That breadth is both the moat and the management challenge.

Pfizer Inc. and Samsung Electronics Co., Ltd. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Pfizer Inc. and Samsung Electronics Co., Ltd..

Pfizer Inc. business model: Pfizer makes money from patented prescription medicines, vaccines, oncology products, hospital therapies, rare disease products, collaborations, and global commercial distribution. Its economics depend on R&D success, regulatory approvals, patent protection, reimbursement, and lifecycle management.

Samsung Electronics Co., Ltd. business model: Samsung earns revenue from memory semiconductors including DRAM, NAND, and HBM; system LSI and foundry; Galaxy smartphones and tablets; display panels; TVs and appliances; network equipment; and Harman automotive and audio products. Memory cycles often drive profits even when smartphones drive brand visibility.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Pfizer Inc. stack up against those of Samsung Electronics Co., Ltd..

Pfizer Inc. competitive advantage: Pfizer advantage is scale: global regulatory expertise, manufacturing capacity, clinical development experience, commercial infrastructure, vaccine capabilities, and the ability to acquire or partner for scientific platforms.

Samsung Electronics Co., Ltd. competitive advantage: Samsung advantage is vertical integration across memory, displays, processors, devices, appliances, and manufacturing. It can supply components to competitors while also using those components in its own Galaxy devices and consumer electronics ecosystem.

Future prospects matter as much as current results. The growth strategies below explain how Pfizer Inc. and Samsung Electronics Co., Ltd. each plan to expand from here.

Pfizer Inc. growth strategy: Pfizer growth strategy emphasizes oncology, vaccines, internal medicine, obesity and metabolic research, business development discipline, cost reduction, and global commercial execution. Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.

Samsung Electronics Co., Ltd. growth strategy: Samsung growth strategy is built around AI memory, HBM3E and HBM4, advanced packaging, 3nm and next-generation foundry nodes, Galaxy AI devices, premium OLED and TV products, connected appliances, networks, and Harman automotive electronics.

A closer look at the financial trajectory of Pfizer Inc. and Samsung Electronics Co., Ltd. rounds out the comparison.

Pfizer Inc.: Pfizer reported $62.579 billion of FY2025 revenue, compared with $63.627 billion in FY2024 and $59.553 billion in FY2023. Net income was $7.771 billion in FY2025. Pfizer employed approximately 75,000 people worldwide as of December 31, 2025.

Samsung Electronics Co., Ltd.: Samsung reported KRW 333.6 trillion in 2025 annual revenue and KRW 43.6 trillion in operating profit. Fourth-quarter revenue reached KRW 93.8 trillion, the highest quarterly consolidated revenue in company history, and fourth-quarter operating profit was KRW 20.1 trillion.